tauroursodeoxycholic
Phase 3Small molecule
tauroursodeoxycholic is one of 9 small molecule programs targeting Cholestatic liver disease. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Cholestatic Liver Disease
#DrugCompanyPhaseTrials
1Rocaltrol
Alnylam PharmaceuticalsApproved
Ursodeoxycholic Acid
Daewoong Pharmaceutical Co. LTD.Phase 3
Actigall
AbbViePhase 2
Livmarli
MMirum Pharmaceuticals, Inc.
Phase 2
Lipaglyn
ZZydus Therapeutics Inc.
Phase 1
LUM001
MMirum Pharmaceuticals, Inc.
Phase 2
tauroursodeoxycholic
BBeijing Trendful Kangjian Medical Information Consulting Limited Company
Phase 3
Epsom Salt
FFresenius Kabi Oncology Ltd.
Preclinical
Magnesium
SSpherium Biomed
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cholestatic liver disease1 trial
Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC
Completed·BBeijing Trendful Kangjian Medical Information Consulting Limited Company·Phase 3·NCT01829698·199 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for tauroursodeoxycholic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details